Search clinical trials for: Raltegravir plus Darunavir/ritonavir

Total 174 results

St Stephens Aids Trust

Completed

Pharmacokinetics (PK) Study of Once Daily Darunavir/Ritonavir and Twice and Once Daily Raltegravir in HIV-infected Subjects

HIV Infections

United Kingdom
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Safety and Effectiveness of Raltegravir Plus Darunavir/Ritonavir in Treatment-Naive HIV-Infected Adults

HIV-1 Infections

United States
McGill University Health Centre/Research Institute...
Merck Sharp & Dohme LLC; CIHR Canadian HIV Trials Network

Completed

Raltegravir Switch Study to Reduce Liver Fibrosis Progression in HIV-Hepatitis C Co-infection

Hepatitis C | HIV | Liver Fibrosis

Canada
ANRS, Emerging Infectious Diseases
Merck Sharp & Dohme LLC; Pfizer; Gilead Sciences; Janssen-Cilag Ltd.

Completed

Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM)

HIV-1 Infections

France
Fundación Huésped
Pfizer

Unknown

Maraviroc (Celsentri) With Raltegravir and Darunavir/Ritonavir for the Treatment of Triple Class Failure in Adult HIV-1 Infected Patients (TERCETO)

AIDS | HIV-1 Adults Patients | Triple Class Failure

Argentina
ANRS, Emerging Infectious Diseases
NEAT - European AIDS Treatment Network

Completed

Study of Darunavir/r + Tenofovir/Emtricitabine vs. Darunavir/r + Raltegravir in HIV-infected Antiretroviral naïve Subjects (ANRS 143)

HIV Infections

Ireland, United Kingdom, Netherlands, France, Spain, Greece, Belgium, Germany, Denmark, Sweden, Italy, Portugal, Austria, Hungary, Poland
St Stephens Aids Trust

Completed

Abacavir Pharmacokinetic Study in the Absence/Presence of Darunavir/Ritonavir or Raltegravir in HIV-infected Subjects

HIV

United Kingdom
St Vincent's Hospital, Sydney
Merck Sharp & Dohme LLC

Completed

Post-prandial Lipid Effects of Raltegravir (RAL) vs Ritonavir -Boosted Darunavir (DRV-r) in Anti-retroviral Therapy (ART)- Naive Adults or Adults Recommencing ART. (ROaR+)

Cardiovascular Disease | HIV

Australia
Janssen-Cilag S.p.A.

Completed

Non-interventional Study on Use of Darunavir With Ritonavir in Clinical Practice

HIV Infections
University of Modena and Reggio Emilia

Completed

A Prospective, Open-label Trial of Two ABC/3TC Based Regimens in Late Presenter naïve Patients (CD4 <200 Cells/µL)

HIV Infection

Italy
East Carolina University

Unknown

Effect of a Non-tenofovir, Non-efavirenz-based HIV Regimen on Bone Density and Vitamin D Levels in African-American Patients With HIV Infection

HIV
French National Agency for Research on AIDS and...
Merck Sharp & Dohme LLC; Janssen-Cilag Tibotec

Completed

Clinical Trial to Assess the Efficacy of Darunavir/Ritonavir (DRV/r), Etravirine (ETV) and Raltegravir (MK-0518) in HIV Patients With Resistant Viruses (ANRS139 TRIO)

HIV Infections

France
Rockefeller University
Merck Sharp & Dohme LLC; Pfizer; Aaron Diamond AIDS Research Center

Completed

Standard Antiretroviral v. Multi-class Therapy in Acutely HIV-1 Infected Antiretroviral-Naïve Subjects (ADARC 2007-01)

HIV Infections

United States
Germans Trias i Pujol Hospital
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la...

Completed

Evaluate the Efficacy and Security of Darunavir/Ritonavir 900/100 mg Once a Day as an Antiretroviral Treatment Simplification Strategy (DRV900100QD)

HIV Infections

Spain
National Center for Global Health and Medicine,...
Ministry of Health, Labour and Welfare, Japan

Completed

Comparing Continuing Tenofovir, Emtricitabine (or Lamivudine) Plus Lopinavir and Switching to Raltegravir Plus Darunavir (SPARE)

HIV Infections

Japan
St Stephens Aids Trust

Completed

Raltegravir Insulin Sensitivity Study

HIV Infections

United Kingdom
Germans Trias i Pujol Hospital

Completed

Clinical Study to Evaluate the Efficacy and Safety of Lopinavir/Ritonavir Monotherapy Versus Darunavir/Ritonavir Monotherapies as Simplification Switching Strategies of PI/NNRTI-Triple Therapy Based-Regimens

HIV Infections

Spain
University of Roma La Sapienza
Istituto Superiore di Sanità

Unknown

Study of Recovery of Intestinal CD4+ and Th17 T Cells in HIV-infected Individuals on Short-term Antiretroviral Therapy

HIV Infection

Italy
Hamad Medical Corporation

Completed

Darunavir/Cobicistat vs. Lopinavir/Ritonavir in COVID-19 Pneumonia in Qatar (DOLCI)

Pneumonia | COVID | Coronavirus

Qatar
Viriom

Completed

Study in Healthy Volunteers to Investigate the Safety, Tolerability and Pharmacokinetics of VM-1500

HIV-infection

Thailand
Ruth M. Rothstein CORE Center
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA

Completed

DRIVESHAFT: Darunavir/Ritonavir In HIV-infected Virologically-suppressed Experienced Subjects (DRIVESHAFT)

HIV

United States
Imperial College London

Terminated

The First Failure Study (FAST)

HIV Infections | HIV

United Kingdom
Tibotec Pharmaceuticals, Ireland

Terminated

TMC114-C227: A Study to Evaluate the Effectiveness and Safety of TMC114 (Darunavir) With a Low Dose of Ritonavir as Monotherapy (no Other Anti-HIV Drugs Will be Given) in Patients Who Have Never Been Treated With Antiretrovirals (Anti-HIV Drugs) Previously

HIV Infections
Juan A. Arnaiz

Unknown

Immune Recovery in Advanced , ARV-naïve, HIV-1-infected Individuals Taking Dolutegravir or Ritonavir-boosted Darunavir

Acquired Immune Deficiency Syndrome Virus

Spain
Giovanni Di Perri
University of Turin, Italy; University of Milan

Terminated

Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir (RALBAT)

HIV Infection | Osteopenia

Italy
St Stephens Aids Trust

Completed

Atazanavir/Ritonavir and Darunavir/Ritonavir PK Tail Study

HIV Infections | HIV

United Kingdom
ANRS, Emerging Infectious Diseases

Unknown

Third Line Antiretroviral Treatment Optimization in Sub-Saharan Africa (THILAO)

HIV Infection

Burkina Faso, Côte D'Ivoire, Mali, Senegal
University of Cincinnati

Completed

Darunavir/Ritonavir and Rosuvastatin Pharmacokinetic Study

HIV Infections

United States
University of Washington
National Institute of Allergy and Infectious Diseases (NIAID); Merck Sharp... and other collaborators

Terminated

RESIST-2: 2nd-line ART for HIV-2 Infection (RESIST-2)

HIV-2 Infection

Senegal
Hoffmann-La Roche

Completed

A Study of Drug-Drug Interaction Between Darunavir and Danoprevir Administered Together With Low-Dose Ritonavir in Healthy Volunteers

Healthy Volunteer

United States
Tibotec Pharmaceuticals, Ireland

Completed

TMC114-TiDP3-C176 - A Study in Healthy Volunteers Investigating the Bioequivalence Between Two Commercially Available 400-mg Tablets to One New 800-mg Tablet of Darunavir (DRV) in the Presence of Low-dose Ritonavir Under Fed and Fasted Conditions

Healthy

Germany
St Stephens Aids Trust

Completed

Double Protease Inhibitor to Darunavir Switch Study

HIV Infections

United Kingdom
International Maternal Pediatric Adolescent AIDS...
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

IMPAACT P1058A: Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults

HIV Infections

United States, Puerto Rico
Tibotec Pharmaceuticals, Ireland

Completed

A Study to Compare Effectiveness and Safety of Darunavir/Ritonavir (DRV/Rtv) 800mg/100mg Once Daily Versus DRV/Rtv 600mg/100mg Twice Daily in Early Treatment-Experienced HIV-1 Infected Patients (ODIN) (ODIN)

Human Immunodeficiency Virus - Type 1

United States, France, United Kingdom, Germany, Taiwan, Spain, Argentina, Chile, Malaysia, Panama, Romania, South Africa, Thailand, Brazil, Puerto Rico, Austria, Hungary, Australia, Guatemala
Tibotec, Inc
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA

Completed

GRACE: A Study to Compare the Effectiveness, Safety and Tolerability of PREZISTA (Darunavir)/Ritonavir by Gender and Race When Administered With Other Antiretroviral Medications in Human Immunodeficiency Virus (HIV) Positive Women and Men.

HIV | Infectious

United States, Canada, Puerto Rico
ANRS, Emerging Infectious Diseases
Institut National de la Santé Et de la Recherche Médicale, France

Completed

Prevention of Perinatal Transmission of HIV-1 Without Nucleoside Reverse Transcriptase Inhibitors (MONOGEST)

Maternal-fetal Infection Transmission

France
Hospitales Universitarios Virgen del Rocío

Completed

Darunavir Levels, Virological Efficacy, Proviral ADN and Resistances in Patients on Darunavir/Ritonavir Monotherapy (MonDar)

HIV-infection

Spain
University of California, Davis

Completed

Mechanisms of Immune Reconstitution & Reduced Immune Activation Following Darunavir-based ART

Human Immunodeficiency Virus Infection

United States
Tibotec BVBA

Completed

VX-950-TiDP24-C124: A Phase I Trial to Investigate the Potential Pharmacokinetic Interactions Between Telaprevir and Darunavir/Ritonavir and Between Telaprevir and Fosamprenavir/Ritonavir at Steady-state.

Hepatitis C | HIV | Telaprevir
Fundação Bahiana de Infectologia

Unknown

Antiretroviral Regimens Containing Raltegravir for Prophylaxis of Mother-to-child-transmission of HIV Infection (PregnantHIV)

Pregnancy | HIV

Brazil
Tibotec, Inc
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA

Completed

Enfuvirtide/Current Protease Inhibitor Switch to PREZISTA (Darunavir)/Ritonavir + TMC125 in HIV Patients With Enfuvirtide Side Effects.

HIV

United States
Merck Sharp & Dohme LLC

Terminated

MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibitor Regimen (0518-032)(TERMINATED)

HIV Infection
Dallas VA Medical Center
Merck Sharp & Dohme LLC; Tibotec Pharmaceutical Limited

Completed

Raltegravir And Darunavir Antiretroviral in Antiretroviral Naive Patients (RADAR)

HIV Infections

United States
Hoffmann-La Roche

Completed

A Study of Drug-Drug Interaction Between Danoprevir/Low-Dose Ritonavir and Raltegravir in Healthy Volunteers

Healthy Volunteer

United States
St Stephens Aids Trust

Terminated

NNRTI/PI Toxicity Switch to Darunavir Study

HIV

United Kingdom
National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

HIV Infections

United States, Puerto Rico, Thailand, Botswana, Argentina, Brazil, Tanzania, South Africa
Hospital Clinic of Barcelona

Completed

Dual Therapy With Raltegravir and Darunavir/Ritonavir in HIV Infected Patients. (RALDAR)

Integrase Inhibitors, HIV; HIV PROTEASE INHIB

Spain
ANRS, Emerging Infectious Diseases

Recruiting

Evaluation of Third-line cART Regimen in Cambodia (3DICAM)

HIV/AIDS

Cambodia
Tibotec, Inc
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA

Completed

A Study to Evaluate the Pharmacokinetic Profile (How the Body Absorbs, Distributes, Metabolizes and Eliminates a Drug) of TMC125 Plus Tenofovir/Emtricitabine Once Daily With or Without Darunavir/r Once Daily in Antiretroviral (ARV) Naive HIV-1 Patients (Patients Have Never Received ARV Treatment).

HIV-1 Infection
St. James's Hospital, Ireland

Unknown

Safety and Efficacy Study Comparing Raltegravir to a Protease Inhibitor in Treatment-naïve, HIV/Hepatitis C Drug Users

HIV Infections | Hepatitis C

Ireland

3

Subscribe